

Document and Entity Information - shares	3 Months Ended	
	Dec. 31, 2015	Nov. 07, 2016
<b>Document and Entity Information [Abstract]</b>		
Entity Registrant Name	MEDICAL INTERNATIONAL TECHNOLOGY INC	
Entity Central Index Key	0001112372	
Amendment Flag	false	
Current Fiscal Year End Date	-09-30	
Document Type	10-Q	
Document Period End Date	Dec. 31, 2015	
Document Fiscal Year Focus	2016	
Document Fiscal Period Focus	Q1	
Entity Filer Category	Smaller Reporting Company	
Entity Common Stock, Shares Outstanding		84,304,627

Consolidated Balance Sheets (Unaudited) - USD (\$)	Dec. 31, 2015	Sep. 30, 2015
<b>Current Assets</b>		
Cash and cash equivalents	\$ 110,160	
Accounts receivable, net of allowance for bad debt of \$7,300 at December 31, 2015	45,270	\$ 57,031
Inventories	206,801	210,579
Prepaid expenses	6,345	7,183
Total Current Assets	368,576	274,793
<b>Property and Equipment</b>		
Tooling and machinery	540,671	558,706
Furniture and office equipment	124,025	128,163
Leasehold improvements	22,133	22,871
Total property and equipment	686,829	709,740
Less accumulated depreciation	(581,044)	(578,738)
Total property and equipment, net	105,785	131,002
<b>Other Assets</b>		
Patents (net of accumulated amortization of \$61,595 and \$56,993)	57,716	53,041
Total assets	\$ 532,077	458,836
<b>Current Liabilities</b>		
Bank line		\$ 74,663
Deferred income	\$ 13,034	
Accounts payable and accrued expenses	\$ 59,986	\$ 109,712
Amounts due to related parties		\$ 30,000
Short term borrowings	\$ 300,000	
Current portion of long term debts	25,683	\$ 35,795
Total Liabilities	\$ 398,703	\$ 250,170
<b>Commitments</b>		
<b>Stockholders' Equity</b>		
Preferred stock, \$0.001 par value; 3,000,000 shares authorized; no issued and outstanding shares as of December 31, 2015 and September 30, 2015.		
Common stock, \$0.001 par value; 100,000,000 shares authorized; 84,304,627 issued and outstanding as of December 31, 2015 and September 30, 2015.	\$ 8,430	\$ 8,430
Additional paid-in capital	12,917,025	12,917,025
Accumulated deficit	(12,391,079)	(12,330,450)
Other comprehensive loss	(401,002)	(386,339)
Total Stockholders' Equity	133,374	208,666
Total Liabilities and Stockholders' Equity	\$ 532,077	\$ 458,836

Consolidated Balance Sheets (Parenthetical) (Unaudited) - USD (\$)	Dec. 31, 2015	Sep. 30, 2015
<b>Balance Sheet [Abstract]</b>		
Accounts receivable, allowance for bad debt	\$ 7,300	
Net of accumulated amortization	\$ 61,595	\$ 56,993
Preferred stock, par value	\$ 0.0001	\$ 0.0001
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued		
Preferred stock, shares outstanding		
Common stock, par value	\$ 0.0001	\$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	84,304,627	84,304,627
Common stock, shares outstanding	84,304,627	84,304,627

Consolidated Statements of Operations (Unaudited) - USD (\$)	3 Months Ended	
	Dec. 31, 2015	Dec. 31, 2014
<b>Statements of Operations [Abstract]</b>		
Sales	\$ 151,237	\$ 132,998
Cost of sales	(41,696)	(42,784)
Gross profit	109,541	90,214
<b>Operating expenses</b>		
Selling, general, and administrative expenses	(168,838)	(99,061)
Total operating expenses	(168,838)	(99,061)
Loss from operations	(59,297)	(8,847)
<b>Other Income (Expense)</b>		
Interest	164	295
Interest expense	(1,496)	(2,398)
Other income (expense), net	(1,332)	(2,103)
Net Loss	\$ (60,629)	\$ (10,950)
Net loss per common share	\$ 0.00	\$ 0.00
Weighted average common shares outstanding - basic and diluted	84,304,627	83,804,627

Consolidated Statements of Cash Flows (Unaudited) - USD (\$)	3 Months Ended	
	Dec. 31, 2015	Dec. 31, 2014
<b>Cash flows from operating activities:</b>		
Net loss	\$ (60,629)	\$ (10,950)
<b>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</b>		
Depreciation and amortization expense	29,324	21,846
<b>Changes in:</b>		
Accounts receivable	11,761	(20,224)
Inventories	3,778	19,708
Prepaid expenses	838	(3,747)
Accounts payable and accrued liabilities	(49,725)	25,760
Deferred income	13,034	3,966
Net cash provided (used) by operating activities	(51,619)	36,359
<b>Cash flows from investing activities:</b>		
Acquisition of patents	\$ (11,430)	(7,557)
Tooling and machinery		(4,613)
Net cash used by investing activities	\$ (11,430)	(12,170)
<b>Cash flows from financing activities:</b>		
Bank line	(74,683)	6,204
Bank loans	(10,112)	\$ (13,632)

Proceeds from short term borrowings	300,000	
Decrease in amounts due to related parties	\$ (30,000)	\$ (20,000)
Repayment on notes payable		(30,000)
Net cash used by financing activities	\$ 185,225	(57,428)
Effect of exchange rates	(12,016)	2,809
Increase (decrease) in cash	\$ 110,160	(30,430)
Cash, beginning of period		33,767
Cash, end of period	\$ 110,160	3,337
<b>Supplemental disclosure of cash flow information:</b>		
Cash paid for interest	\$ 1,496	\$ 2,398
Cash paid for federal income taxes		

Consolidated Statements of Comprehensive Loss (Unaudited) - USD (\$)	3 Months Ended	
	Dec. 31, 2015	Dec. 31, 2014
<b>Statements of Comprehensive Loss [Abstract]</b>		
Net loss	\$ (60,629)	\$ (10,950)
<b>Other comprehensive loss</b>		
Foreign currency translation adjustment	(14,663)	(8,953)
Net comprehensive loss	\$ (75,292)	\$ (19,903)

Basis of Presentation	3 Months Ended	
	Dec. 31, 2015	
<b>Basis of Presentation [Abstract]</b>		
Basis of Presentation	<b>Note 1 – Basis of Presentation</b>	
<b>Interim Financial Statements</b>		
<p>The accompanying unaudited condensed consolidated financial statements of Medical International Technology, Inc. (“MIT” or the “Company”) and its subsidiary (collectively referred to as the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America, pursuant to the rules and regulations of the Securities and Exchange Commission. All significant intercompany balances and transactions have been eliminated. These financial statements do not include all information and notes required by accounting principles generally accepted in the United States of America for complete financial statements. It is recommended that these interim unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2015.</p> <p>In the opinion of management, all adjustments (consisting only of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three month period ended December 31, 2015 are not necessarily indicative of the results which may be expected for any other interim periods or for the year ending September 30, 2016. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</p> <p>Going concern</p> <p>There can be no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company’s existing stockholders.</p> <p>The accompanying financial statements do not include any adjustments related to the recoverability or classification of asset carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.</p>		

Inventories	3 Months Ended	
	Dec. 31, 2015	
<b>Inventories [Abstract]</b>		
Inventories	<b>Note 2 – Inventories</b>	
<p>Inventories at December 31, 2015 and September 30, 2015 consist of the following:</p>		
	December 31,	\$
	2015	
Raw materials	\$ 137,361	\$
Work in process	47,180	
Finished goods	22,260	
Total	<u>\$ 206,801</u>	<u>\$</u>

Property and Equipment	3 Months Ended	
	Dec. 31, 2015	
<b>Property and Equipment [Abstract]</b>		
Property and Equipment	<b>Note 3 – Property and Equipment</b>	
<p>The cost of property and equipment is depreciated over the estimated useful lives of the related assets, which range from 5 to 7 years. Depreciation is computed on the straight-line method for financial reporting purposes and on the declining balance method for income tax reporting purposes. Depreciation expense for the three months ended December 31, 2015 and 2014 was \$23,358 and \$16,813, respectively.</p>		

Intangible Assets	3 Months Ended	
	Dec. 31, 2015	
<b>Intangible Assets [Abstract]</b>		
Intangible Assets	<b>Note 4 – Intangible Assets</b>	
<p>As of December 31, 2015 the Company has net patents on certain technologies aggregating \$57,716. Amortization expense for the three months ended December 31, 2015 and 2014 were \$5,966 and \$5,033, resp three months ended December 31, 2015, the Company capitalized patent costs on its needle-free injector of \$11,430. Following is a detail of patents at December 31, 2015.</p>		
	Gross Intangible Assets	Net Intangible Assets
	\$ 119,310	\$ 57,716
Patents	\$ 119,310	\$ 57,716
	\$ 61,594	\$

Joint venture agreement	3 Months Ended	
	Dec. 31, 2015	
<b>Joint venture agreement [Abstract]</b>		
Joint venture agreement	<b>Note 5 – Joint venture agreement</b>	
<p>On May 6, 2009, the Company entered into a certain joint venture agreement (the “Joint Venture Agreement”) with Jianguo Hualan Biotechnology Ltd. (China) (“Jianguo Hualan”). Pursuant to the Joint Venture Agreement, the parties thereto established a joint venture company, Jianguo Hualan MIT Medical Technology (MIT China) Ltd. (“MIT China” or the “Joint Venture”), focusing on research, production and sales of medical equipments, import and export of medical equipments and components products, especially Needle-Free Jet Injector products. The total investment by the Joint Venture shall amount to \$2,000,000, and the registered capital shall amount to \$1,400,000. The Company invested cash of \$426,678 and transferred the license rights to produce and sell the Company’s needle-free injectors products into the Joint Venture. The license rights were valued at \$280,000 under the agreement. The contributions by the Company resulted in the Company owning 49% of the registered capital of the Joint Venture. Jianguo Hualan contributed cash of \$714,000, and owns 51% of the registered capital.</p> <p>Under the Joint Venture Agreement, the Company appointed 1 member, and Jianguo Hualan appointed 2 members, to the board of directors of the Joint Venture. Profits of the Joint Venture will be allocated based upon each party’s investment in the registered capital.</p> <p>In March 2012, MIT China agreed and sold 9% of the joint venture for an investment of 18,000,000 RMB (US\$3,000,000). Jianguo Hualan now has 46.41%, the Company has 44.59%, and Taizhou Amazon Investment Center has 9% ownership in the MIT China joint venture.</p> <p>The Company accounts for its investment in MIT China in accordance with Financial Accounting Standards Board Accounting Standards Codification 323, “Investment — Equity Method and Joint Venture” (ASC 323), previously referred to as Accounting Principles Board Opinion No. 18, “The Equity Method of Accounting for Investments in Common Stock.” Accordingly, the Company adjusts the carrying amount of its investment in MIT China to recognize its share of earnings or losses. As of December 31, 2015 and September 30, 2015, the Company’s had no recorded investment remaining in the MIT China.</p> <p>During the three months ended December 31, 2015, the Company had \$43,830 in sales of products to the joint venture. As of December 31, 2015 and September 30, 2015, the Company had a receivable from the joint venture of \$45,270 and \$51,165, respectively.</p> <p>During the three months ended December 31, 2014, the Company had \$66,290 in sales of products to the joint venture.</p>		

Bank Line	3 Months Ended Dec. 31, 2015
<b>Bank Line [Abstract]</b>	
Bank Line	<b>Note 6 – Bank Line</b>
The Company, through a hypothec agreement, has a line of credit up to a maximum of \$100,000. The line is secured by Investissement Quebec (a Quebec government entity) and by Karim Menassa (personally) and by account receivables, inventories, equipment and all other assets of the Company. The line bears interest at the prime rate plus 2.5% (5.75% at September 30, 2015). At December 31, 2015 and September 30, 2015, the Company had \$0 and \$74,663 outstanding under the agreement.	

Related Party Transactions	3 Months Ended Dec. 31, 2015
<b>Related Party Transactions [Abstract]</b>	
Related Party Transactions	<b>Note 7 – Related Party Transactions</b>
Related party balances consist of the following at December 31, 2015 and September 30, 2015:	
	December 31, 2015
Payable to 9211-0766 Quebec Inc bearing interest at 8% and due December 31, 2015	\$ -
	\$ -
During the three months ended December 31, 2015 and 2014, the Company paid approximately \$82,000 and \$48,000 to a company owned by the President and CEO for consulting fees.	

Stockholders' Equity (Deficit)	3 Months Ended Dec. 31, 2015
<b>Stockholders' Equity (Deficit) [Abstract]</b>	
Stockholders' Equity (Deficit)	<b>Note 8 – Stockholders' Equity (Deficit)</b>
<b>Issuance of Common Stock</b>	
From time to time, the Company will issue common stock for services rendered, debt reductions or as part of private placement offerings.	
For the quarter ended December 31, 2015, there was no common stock issuance.	
<b>Preferred Stock</b>	
As of December 31, 2015, there was no preferred stock outstanding. Dividend features and voting rights are at the discretion of the Board of Directors without the requirement of shareholder approval.	
<b>Outstanding Options</b>	
As of December 31, 2015 and 2014, there are no options outstanding to purchase shares of the Company's common stock.	
<b>Outstanding Warrants</b>	
There are no outstanding warrants	

Operating Leases	3 Months Ended Dec. 31, 2015
<b>Operating Leases [Abstract]</b>	
Operating Leases	<b>Note 9 – Operating Leases</b>
The Company leases its office and warehouse space under an operating lease that expires on December 31, 2021. The lease calls for a monthly rent of \$3,600 (CND). Rent expense for the three months ended Dec approximately \$11,050.	
Future minimum lease commitments pertaining to the lease expire as follow:	
Year ended	
December 31, 2016	\$ -
December 31, 2017	
December 31, 2018	
December 31, 2019	
December 31, 2020	
December 31, 2021	
	\$ -

Debt	3 Months Ended Dec. 31, 2015
<b>Debt [Abstract]</b>	
Debt	<b>Note 10 – Debt</b>
Debt consists of the following at December 31, 2015 and September 30, 2015:	
	December 31, 2015
Note payable to a bank, bearing interest at prime plus 3% (6.25% at September 30, 2015), secured by equipment, due December 20, 2016.	\$ 18,405
Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) Equal and consecutive quarterly installments of \$5,035 (CND) through May 2016.	7,278
Short term borrowing payable to an individual, bearing zero interest and no payment terms or maturity date	300,000
Total debt (all current)	\$ 325,683

Contingencies	3 Months Ended Dec. 31, 2015
<b>Contingencies [Abstract]</b>	
Contingencies	<b>Note 11 – Contingencies</b>
<b>Legal Proceedings</b>	
We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries' officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.	

Inventories (Tables)	3 Months Ended Dec. 31, 2015
<b>Inventories [Abstract]</b>	
Schedule of inventories	
Raw materials	
Work in process	
Finished goods	
Total	

Intangible Assets (Tables)	3 Months Ended Dec. 31, 2015
<b>Intangible Assets [Abstract]</b>	
Summary of patents	Accumulated Amortization

Patents	\$ 119,310	\$
---------	------------	----

Related Party Transactions (Tables)	3 Months Ended
Related Party Transactions [Abstract]	Dec. 31, 2015
Schedule of related party transactions	
Payable to 9211-0766 Quebec Inc bearing interest at 8% and due December 31, 2015	

Operating Leases (Tables)	3 Months Ended
Operating Leases [Abstract]	Dec. 31, 2015
Schedule of future minimum lease commitments	
Year ended	
December 31, 2016	
December 31, 2017	
December 31, 2018	
December 31, 2019	
December 31, 2020	
December 31, 2021	

Debt (Tables)	3 Months Ended	December 31, 2015	\$
Debt [Abstract]	Dec. 31, 2015		
Schedule of long-term debt			
Note payable to a bank, bearing interest at prime plus 3% (6.25% at September 30, 2015), secured by equipment, due December 20, 2016.			
Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) Equal and consecutive quarterly installments of \$5,035 (CND) through May 2016.		7,278	
Short term borrowing payable to an individual, bearing zero interest and no payment terms or maturity date		300,000	
Total debt (all current)		<u>\$ 325,683</u>	<u>\$</u>

Inventories (Details) - USD (\$)	Dec. 31, 2015	Sep. 30, 2015
<b>Components of inventories</b>		
Raw materials	\$ 137,361	\$ 136,842
Work in process	47,180	51,511
Finished goods	22,260	22,228
Total	<u>\$ 206,801</u>	<u>\$ 210,579</u>

Property and Equipment (Details) - USD (\$)	3 Months Ended	Dec. 31, 2015	Dec. 31, 2014
<b>Property and Equipment (Textual)</b>			
Property and equipment, estimated useful lives			
The cost of property and equipment is depreciated over the estimated useful lives of the related assets, which range from 5 to 7 years.			
Depreciation expense		\$ 23,358	\$ 16,813

Inangible Assets (Details) - USD (\$)	3 Months Ended	
	Dec. 31, 2015	Sep. 30, 2015
<b>Detail of patents</b>		
Accumulated amortization	\$ 61,595	\$ 56,993
Net Intangible Assets	57,716	\$ 53,041
<b>Patents [Member]</b>		
<b>Detail of patents</b>		
Gross Intangible Assets	119,310	
Accumulated amortization	61,594	
Net Intangible Assets	\$ 57,716	
<b>Patents [Member]   Maximum [Member]</b>		
<b>Detail of patents</b>		
Weighted Average Life (Years)	15 years	
<b>Patents [Member]   Minimum [Member]</b>		
<b>Detail of patents</b>		
Weighted Average Life (Years)	7 years 6 months	

Inangible Assets (Details Textual) - USD (\$)	3 Months Ended		
	Dec. 31, 2015	Dec. 31, 2014	Sep. 30, 2015
<b>Inangible Assets (Textual)</b>			
Aggregate net patents	\$ 57,716		\$ 53,041
Amortization expenses	5,966	\$ 5,033	
Capitalized patent costs on needle-free injector	\$ 11,430		

Joint venture agreement (Details)	May. 06, 2009 USD (\$) Members	1 Months Ended	3 Months Ended			Mar. 31, 2012 CNY (¥)
		Mar. 31, 2012 USD (\$)	Dec. 31, 2015 USD (\$)	Dec. 31, 2014 USD (\$)	Sep. 30, 2015 USD (\$)	
<b>Joint Venture Agreement (Textual)</b>						
Ownership percentage	49.00%	44.59%				44.59%
Cash invested in joint venture		\$ 3,000,000				¥ 18,000,000
Number of members appointed under joint venture agreement   Members	1					
Total investment to be made by joint venture	\$ 2,000,000					
Registered capital	1,400,000					
Investment in joint venture	426,678					
Value of license rights	\$ 280,000					
Sale of joint venture percentage for an investment by parent company		9.00%				
Sale of products to joint venture, amount			\$ 43,830	\$ 66,290		
Receivable			\$ 45,270		\$ 51,165	
<b>Jiangsu Hualan [Member]</b>						
<b>Joint Venture Agreement (Textual)</b>						
Ownership percentage	51.00%	46.41%				46.41%
Cash invested in joint venture	\$ 714,000					
Number of members appointed under joint venture agreement   Members	2					
<b>Taizhou Amazon Investment Center [Member]</b>						
<b>Joint Venture Agreement (Textual)</b>						
Ownership percentage		9.00%				9.00%

Bank Line (Details) - USD (\$)	3 Months Ended	
	Dec. 31, 2015	Sep. 30, 2015
<b>Bank Line (Textual)</b>		
Maximum equipment line of credit	\$ 100,000	
Amount outstanding	\$ 0	\$ 74,663
Interest prime rate	2.50%	
Line bears interest rate		5.75%

Related Party Transactions (Details) - USD (\$)	Dec. 31, 2015	Sep. 30, 2015
	<b>9211-0766 Quebec Inc [Member]</b>	
<b>Related Party Transaction [Line Items]</b>		
Payable to 9211-0766 Quebec Inc bearing interest at 8% and due December 31, 2015		\$ 30,000

Related Party Transactions (Details Textual) - USD (\$)	3 Months Ended	
	Dec. 31, 2015	Dec. 31, 2014
<b>Related Party Transaction (Textual)</b>		
Interest rate percent	8.00%	
<b>CEO [Member]</b>		
<b>Related Party Transaction (Textual)</b>		
Consulting fees	\$ 82,000	\$ 48,000
<b>President [Member]</b>		
<b>Related Party Transaction (Textual)</b>		
Consulting fees	\$ 82,000	\$ 48,000

Operating Leases (Details)	Sep. 30, 2015 USD (\$)
<b>Future minimum lease commitments</b>	
December 31, 2016	\$ 26,000
December 31, 2017	27,000
December 31, 2018	30,000
December 31, 2019	30,000
December 31, 2020	30,000
December 31, 2021	30,000
Total	<u>\$ 173,000</u>

Operating Leases (Details Textual)	3 Months Ended	
	Dec. 31, 2015 USD (\$)	Dec. 31, 2015 CAD
<b>Operating Leases (Textual)</b>		
Expiry date of operating lease	Dec. 31, 2021	Dec. 31, 2021
Monthly rent for office and warehouse space		CAD 3,600
Rent expense   \$	\$ 11,050	

Debt (Details) - USD (\$)	Dec. 31, 2015	Sep. 30, 2015
<b>Schedule of long-term debt</b>		
Note payable to a bank, bearing interest at prime plus 3% (6.25% at September 30, 2015), secured by equipment, due December 20, 2016.	\$ 18,405	\$ 24,515
Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) Equal and consecutive quarterly installments of \$5,035 (CND) through May 2016.	7,278	\$ 11,280
Short term borrowing payable to an individual, bearing zero interest and no payment terms or maturity date	300,000	
Total debt (all current)	<u>\$ 25,683</u>	<u>\$ 35,795</u>

Debt (Details Textual)	3 Months Ended		12 Months Ended
	Dec. 31, 2015 CAD Numbers		Sep. 30, 2015
<b>Notes Payable to Banks [Member]</b>			
<b>Debt (Textual)</b>			
Interest rate in addition to prime rate		3.00%	6.25%
Debt maturity date	Dec. 20, 2016		
<b>Canada economic development [Member]</b>			
<b>Debt (Textual)</b>			
Number of consecutive installments for repayment of long-term debt   Numbers		16	
Repayment of interest		CAD 5,035	
Debt maturity date	May 31, 2016		
Due date description of first installment	Repayment of the contribution in sixteen (16) Equal and consecutive quarterly installments.		

**The rendering log information**

Info : In "Consolidated Balance Sheets (Unaudited)", column(s) 3, 4 are contained in other reports, so were removed by flow through suppression.  
Info : In "Consolidated Statements of Operations (Unaudited)", column(s) 7, 8 are contained in other reports, so were removed by flow through suppression.  
Info : In "Consolidated Statements of Cash Flows (Unaudited)", column(s) 3, 4 are contained in other reports, so were removed by flow through suppression.  
Info : In "Consolidated Statements of Comprehensive Loss (Unaudited)", column(s) 3, 4 are contained in other reports, so were removed by flow through suppression.